Denschlag, Dominik and Czogalla, Bastian and Heitz, Florian and Kerkmann, Markus and Fangmann, Laura-Christin and Klecker, Philip H. and Stuebs, Frederik A. and Wolber, Linn and Radosa, Julia and Lodde, Pia C. and Seitz, Stephan and George, Christian and Mach, Pawel and Fink, Angelina and Bokhua, Davit and deGregorio, Nikolaus and Lampe, Bjorn and Hemptenmacher, Franziska and Friebe, Verena and Fleisch, Markus and Wimberger, Pauline and Jaeger, Anna and Schnelzer, Andreas and Mittelstadt, Suzana and Ratiu, Dominik and Eichbaum, Michael and Haus, Adriana and Kalder, Matthias and Ataseven, Beyhan and Schroder, Willibald and Bronger, Holger and Kosse, Jens and Ulrich, Uwe Andreas and Elser, Gabriele and Harter, Philipp (2025) Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus. GEBURTSHILFE UND FRAUENHEILKUNDE, 85 (5). pp. 520-532. ISSN 0016-5751, 1438-8804
Full text not available from this repository. (Request a copy)Abstract
Introduction Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking. Methods This first national quality assurance initiative was a retrospective analysis of patients with r/mCC diagnosed between 2018 and 2022, who were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free (PFS) and overall survival (OS) were calculated using Kaplan-Meier analysis. Results A total of 503 eligible patients (median age 55 years) were analyzed for r/mCC. 276/503 patients (55%) received first-line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted antibody therapy with bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment (the remaining 6/503 patients received immunotherapy only). For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95% CI 11-14), 8.8 months (95% CI 7.1-11), and 3 months (95% CI 2.3-4.8), and OS was 25 months (95% CI 21-31), 17 months (95% CI 14-22), and 3.6 months (95% CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second-line (2L) therapy. Conclusion Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including antibody therapy according to national guidelines. Moreover, 22% at initial diagnosis and 38% of patients at PD were not treated with systemic therapy at all. This might reflect poor general performance status, patients' preference, and/or lack of effective therapies especially in 2L treatment.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PREVIOUSLY TREATED RECURRENT; PHASE-III TRIAL; TISOTUMAB VEDOTIN; OPEN-LABEL; CISPLATIN; SURVIVAL; PATTERNS; metastatic cervical cancer; real-world data; quality assurance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Mar 2026 12:54 |
| Last Modified: | 26 Mar 2026 12:54 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67971 |
Actions (login required)
 |
View Item |
